JAMA Network October 16, 2020
Jesse L. Goodman, MD, MPH; John D. Grabenstein, RPh, PhD; M. Miles Braun, MD, MPH

The US government is investing in rapid development of vaccines against coronavirus disease 2019 (COVID-19), several relying on new technologies.1 In the US, 4 vaccine candidates are in phase 3 studies with initial results expected soon. If studies succeed, 1 or more vaccines may become available within a few months. Clinicians are likely among the first to be offered COVID-19 vaccines and have a key role in helping patients make decisions about vaccination.2 Providing evidence-based information will be particularly important in an environment of polarization and mistrust. This Viewpoint focuses on common questions patients are likely to ask about COVID-19 vaccines.

How Much Does a Vaccine Reduce the Risk of COVID-19 and Its Complications?

The US Food and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
The Ripple Effect: Ways to Make Health in All Policies Stick in Kansas and Beyond to Enhance Health and Equity
Research Funding Is Needed To Support An Effective, Equitable, And Sustainable Public Health System
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
New Data: Long COVID Cases Surge
New federal health IT strategy increases focus on public health, AI

Share This Article